Results for
""Mitoxantrone""[mesh_terms]

Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.

Rebecca Anderson, Lance D Miller, Scott Isom, Jeff W Chou, Kristin M Pladna, Nathaniel J Schramm, Leslie R Ellis, Dianna S Howard, Rupali R Bhave, Megan Manuel, Sarah Dralle, Susan Lyerly, Bayard L Powell, Timothy S Pardee

Nature communications 2022;13(1):1673

Higher risk of hepatotoxicity associated with cabozantinib in cancer patients.

Wenli Li, Xin Lv, Hang Yin, Lili Jiang, Yong Liu, Zhen Wang, Zhe Wang

Critical reviews in oncology/hematology 2024;196():104298

The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.

Gregory Heath, Archana Airody, Richard Peter Gale

Drugs 2017;77(3):303-311

A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.

Amy Y Wang, Howard Weiner, Margaret Green, Hua Chang, Noreen Fulton, Richard A Larson, Olatoyosi Odenike, Andrew S Artz, Michael R Bishop, Lucy A Godley, Michael J Thirman, Satyajit Kosuri, Jane E Churpek, Emily Curran, Kristen Pettit, Wendy Stock, Hongtao Liu

Journal of hematology & oncology 2019;11(1):4

Targeting of drug-loaded nanoparticles to tumor sites increases cell death and release of danger signals.

Magdalena Alev, Laura Egenberger, Laura Mühleisen, Bianca Weigel, Benjamin Frey, Ralf P Friedrich, Marina Pöttler, Christoph Alexiou, Christina Janko

Journal of controlled release : official journal of the Controlled Release Society 2019;285():67-80

Two cases of isolated symptomatic myocarditis induced by all-trans retinoic acid (ATRA).

Saskia K Klein, Bart J Biemond, Marinus H J van Oers

Annals of hematology 2008;86(12):917-8

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.

Anna B Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, Kelsey-Leigh A Garcia, Mary-Elizabeth M Percival, Ryan D Cassaday, Vivian G Oehler, Pamela S Becker, Jacob S Appelbaum, Janis L Abkowitz, Johnnie J Orozco, Siobán B Keel, Paul C Hendrie, Bart L Scott, M Cristina Ghiuzeli, Elihu H Estey, Roland B Walter

Blood advances 2023;7(17):4950-4961

Therapeutic options in androgen-independent prostate cancer: building on docetaxel.

Daniel Petrylak

BJU international 2006;96 Suppl 2():41-6

Calcium-phosphate homeostasis in secondary progressive multiple sclerosis patients during mitoxantrone therapy.

Martyna Lis, Natalia Niedziela, Maria Nowak-Kiczmer, Katarzyna Kubicka-Bączyk, Monika Adamczyk-Sowa

Neurological research 2022;43(12):1050-1055

Phase I study of mitoxantrone, raltitrexed, levofolinic acid and 5-fluorouracil in advanced solid tumours.

F Caponigro, A Avallone, F Rivellini, P Comella, F Ionna, V De Rosa, G Comella

Cancer chemotherapy and pharmacology 2001;47(2):113-6

The modulation by xanthines of the DNA-damaging effect of polycyclic aromatic agents. Part II. The stacking complexes of caffeine with doxorubicin and mitoxantrone.

Jacek Piosik, Malgorzata Zdunek, Jan Kapuscinski

Biochemical pharmacology 2002;63(4):635-46

Adjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study.

Erkan Topuz, Mert Basaran, Pinar Saip, Adnan Aydiner, Andac Argon, Burak Sakar, Faruk Tas, Kazim Uygun, Dursun Bugra, N Faruk Aykan

American journal of clinical oncology 2003;25(6):619-24

Regional chemotherapy of nonresectable colorectal liver metastases with mitoxantrone, 5-fluorouracil, folinic acid, and mitomycin C may prolong survival.

K H Link, E Sunelaitis, M Kornmann, M Schatz, F Gansauge, G Leder, A Formentini, L Staib, J Pillasch, H G Beger

Cancer 2001;92(11):2746-53

Mitoxantrone-loaded superparamagnetic iron oxide nanoparticles as drug carriers for cancer therapy: Uptake and toxicity in primary human tubular epithelial cells.

Iwona Cicha, Laura Scheffler, Astrid Ebenau, Stefan Lyer, Christoph Alexiou, Margarete Goppelt-Struebe

Nanotoxicology 2016;10(5):557-66